NCT04873323View on ClinicalTrials.gov

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
Healthy Subjects
Interventions
DRUG

TS-142

Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period

DRUG

Moxifloxacin

Single dose of moxifloxacin 400 mg in the morning under fasting in each period

DRUG

Placebo

Single dose of TS-142 placebo in the morning under fasting in each period

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Toshima-ku

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY